Spectrum Pharmaceuticals, Inc. – NASDAQ:SPPI
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 4 hours
Spectrum Pharmaceuticals stock price monthly change
-14.17%
month
Spectrum Pharmaceuticals stock price quarterly change
+32.48%
quarter
Spectrum Pharmaceuticals stock price yearly change
+33.52%
year
Spectrum Pharmaceuticals key metrics
Market Cap | 210.37M |
Enterprise value | 100.12M |
P/E | -1.57 |
EV/Sales | 2567.35 |
EV/EBITDA | -0.94 |
Price/Sales | 3260.04 |
Price/Book | 3.54 |
PEG ratio | -0.07 |
EPS | -0.36 |
Revenue | N/A |
EBITDA | -61.88M |
Income | -65.05M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -272128.21% |
Oper. margin | -251041.03% |
Gross margin | -7.69% |
EBIT margin | -251041.03% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeSpectrum Pharmaceuticals stock price history
Spectrum Pharmaceuticals stock forecast
Spectrum Pharmaceuticals financial statements
| Jun 2022 | 39K | -29.04M | -74474.36% |
|---|---|---|---|
| Sep 2022 | 0 | -21.92M | |
| Dec 2022 | 10.11M | -8.93M | -88.38% |
| Mar 2023 | 15.61M | -5.14M | -32.94% |
| Jun 2022 | 79429000 | 45.98M | 57.9% |
|---|---|---|---|
| Sep 2022 | 118929000 | 83.07M | 69.85% |
| Dec 2022 | 103338000 | 75.45M | 73.01% |
| Mar 2023 | 107675000 | 80.87M | 75.11% |
| Jun 2022 | -23.44M | -34.90M | 5.20M |
|---|---|---|---|
| Sep 2022 | -17.90M | -1.76M | 50.46M |
| Dec 2022 | -25.33M | 9.52M | -78K |
| Mar 2023 | -21.44M | 31.33M | 2.11M |
Spectrum Pharmaceuticals alternative data
| Aug 2023 | 86 |
|---|---|
| Sep 2023 | 86 |
| Oct 2023 | 86 |
| Nov 2023 | 86 |
| Dec 2023 | 86 |
| Jan 2024 | 86 |
| Feb 2024 | 86 |
| Mar 2024 | 86 |
| Apr 2024 | 86 |
| May 2024 | 86 |
| Jun 2024 | 86 |
| Jul 2024 | 86 |
Spectrum Pharmaceuticals other data
34.44%
-11.67%
of SPPI is owned by hedge funds
76
-14
58.45M
-12.95M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jun 2022 | 0 | 30609 |
| Nov 2022 | 50000 | 0 |
| Jan 2023 | 0 | 267894 |
| Feb 2023 | 0 | 67384 |
| Mar 2023 | 0 | 92464 |
| May 2023 | 0 | 32387 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | BRENNAN NORA officer: CFO | Common Stock, $0.001 par value | 32,387 | $1.1 | $35,496 | ||
Sale | MCGAHAN KEITH M officer: Chief Le.. | Common Stock, $0.001 par value | 27,197 | $0.8 | $21,649 | ||
Sale | RIGA THOMAS J director, officer.. | Common Stock, $0.001 par value | 31,381 | $0.8 | $24,979 | ||
Sale | MCGAHAN KEITH M officer: Chief Le.. | Common Stock, $0.001 par value | 15,733 | $0.82 | $12,885 | ||
Sale | RIGA THOMAS J director, officer.. | Common Stock, $0.001 par value | 18,153 | $0.82 | $14,867 | ||
Sale | MCGAHAN KEITH M officer: Chief Le.. | Common Stock, $0.001 par value | 18,385 | $0.77 | $14,156 | ||
Sale | MCGAHAN KEITH M officer: Chief Le.. | Common Stock, $0.001 par value | 11,990 | $0.76 | $9,124 | ||
Sale | RIGA THOMAS J director, officer.. | Common Stock, $0.001 par value | 22,402 | $0.77 | $17,250 | ||
Sale | RIGA THOMAS J director, officer.. | Common Stock, $0.001 par value | 14,607 | $0.76 | $11,116 | ||
Sale | MCGAHAN KEITH M officer: Chief Le.. | Common Stock, $0.001 par value | 41,014 | $0.62 | $25,429 |
| Patent |
|---|
Grant Filling date: 14 Jun 2016 Issue date: 13 Sep 2022 |
Application Filling date: 28 Jan 2022 Issue date: 19 May 2022 |
Grant Filling date: 31 May 2019 Issue date: 8 Mar 2022 |
Application Filling date: 12 Sep 2019 Issue date: 10 Feb 2022 |
Application Filling date: 13 Jul 2021 Issue date: 20 Jan 2022 |
Application Filling date: 20 Sep 2019 Issue date: 18 Nov 2021 |
Application Filling date: 25 Jun 2019 Issue date: 26 Aug 2021 |
Application COMBINATION OF POZIOTINIB WITH CYTOTOXIC AGENT AND/OR OTHER MOLECULARLY TARGETED AGENT AND USE THEREOF Filling date: 25 Jun 2019 Issue date: 20 May 2021 |
Application Filling date: 18 Aug 2020 Issue date: 14 Jan 2021 |
Application Filling date: 18 Oct 2018 Issue date: 20 Aug 2020 |
| Quarter | Transcript |
|---|---|
| Q4 2022 22 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 10 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 11 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 12 May 2022 | Q1 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Thomas J. Riga (1975) Pres, Chief Executive Officer & Director | $1,030,000 |
| Mr. Kurt A. Gustafson (1968) Executive Vice President & Chief Financial Officer | $953,390 |
Dr. Francois J. Lebel FRCPC, M.D. (1952) Executive Vice President & Chief Medical Officer | $926,760 |
| Mr. Keith M. McGahan J.D., L.L.M. (1976) Executive Vice President, Chief Legal Officer & Corporation Sec. | $842,190 |
Spectrum's Rolvedon A Differentiator In A $3B/Yr Market
Assertio: Cheap And Growing Disruptor Of Pharma's Antiquated Sales Model
Assertio Holdings: A Little More Risk, A Lot Higher Reward
Cullinan Oncology: One Of The Leaders In Cancer Treatment Development
Spectrum Pharmaceuticals' CRL: There Is Very Little Clarity
BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space
Spectrum's Big Approval: Any Day Now
ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas
Spectrum Pharmaceuticals: Rolontis Korean Facility Inspection Presents Opportunity
-
When is Spectrum Pharmaceuticals's next earnings date?
Unfortunately, Spectrum Pharmaceuticals's (SPPI) next earnings date is currently unknown.
-
Does Spectrum Pharmaceuticals pay dividends?
No, Spectrum Pharmaceuticals does not pay dividends.
-
How much money does Spectrum Pharmaceuticals make?
Spectrum Pharmaceuticals has a market capitalization of 210.37M.
-
What is Spectrum Pharmaceuticals's stock symbol?
Spectrum Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "SPPI".
-
What is Spectrum Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Spectrum Pharmaceuticals?
Shares of Spectrum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Spectrum Pharmaceuticals's key executives?
Spectrum Pharmaceuticals's management team includes the following people:
- Mr. Thomas J. Riga Pres, Chief Executive Officer & Director(age: 50, pay: $1,030,000)
- Mr. Kurt A. Gustafson Executive Vice President & Chief Financial Officer(age: 57, pay: $953,390)
- Dr. Francois J. Lebel FRCPC, M.D. Executive Vice President & Chief Medical Officer(age: 73, pay: $926,760)
- Mr. Keith M. McGahan J.D., L.L.M. Executive Vice President, Chief Legal Officer & Corporation Sec.(age: 49, pay: $842,190)
-
How many employees does Spectrum Pharmaceuticals have?
As Jul 2024, Spectrum Pharmaceuticals employs 86 workers.
-
When Spectrum Pharmaceuticals went public?
Spectrum Pharmaceuticals, Inc. is publicly traded company for more then 28 years since IPO on 26 Sep 1996.
-
What is Spectrum Pharmaceuticals's official website?
The official website for Spectrum Pharmaceuticals is sppirx.com.
-
Where are Spectrum Pharmaceuticals's headquarters?
Spectrum Pharmaceuticals is headquartered at Pilot House – Lewis Wharf, Boston, MA.
-
How can i contact Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals's mailing address is Pilot House – Lewis Wharf, Boston, MA and company can be reached via phone at +61 75863900.
Spectrum Pharmaceuticals company profile:
Spectrum Pharmaceuticals, Inc.
sppirx.comExchange:
NASDAQ
Full time employees:
86
Industry:
Biotechnology
Sector:
Healthcare
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations; and Anti-CD20-IFNa, an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma, including diffuse large B-cell lymphoma. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and in-license agreement with ImmunGene, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is based in Boston, Massachusetts.
Pilot House – Lewis Wharf
Boston, MA 02110
Boston, MA 02110
CIK: 0000831547
ISIN: US84763A1088
CUSIP: 84763A108
